149 related articles for article (PubMed ID: 37035456)
1. Circulating indian hedgehog is a marker of the hepatocyte-TAZ pathway in experimental NASH and is elevated in humans with NASH.
Moore MP; Wang X; Shi H; Meroni M; Cherubini A; Ronzoni L; Parks EJ; Ibdah JA; Rector RS; Valenti L; Dongiovanni P; Tabas I
JHEP Rep; 2023 May; 5(5):100716. PubMed ID: 37035456
[TBL] [Abstract][Full Text] [Related]
2. Hepatocyte-targeted siTAZ therapy lowers liver fibrosis in NASH diet-fed chimeric mice with hepatocyte-humanized livers.
Wang X; Moore MP; Shi H; Miyata Y; Donnelly SK; Radiloff DR; Tabas I
Mol Ther Methods Clin Dev; 2023 Dec; 31():101165. PubMed ID: 38144682
[TBL] [Abstract][Full Text] [Related]
3. Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis.
Wang X; Zheng Z; Caviglia JM; Corey KE; Herfel TM; Cai B; Masia R; Chung RT; Lefkowitch JH; Schwabe RF; Tabas I
Cell Metab; 2016 Dec; 24(6):848-862. PubMed ID: 28068223
[TBL] [Abstract][Full Text] [Related]
4. TAZ-induced Cybb contributes to liver tumor formation in non-alcoholic steatohepatitis.
Wang X; Zeldin S; Shi H; Zhu C; Saito Y; Corey KE; Osganian SA; Remotti HE; Verna EC; Pajvani UB; Schwabe RF; Tabas I
J Hepatol; 2022 Apr; 76(4):910-920. PubMed ID: 34902531
[TBL] [Abstract][Full Text] [Related]
5. Cholesterol Stabilizes TAZ in Hepatocytes to Promote Experimental Non-alcoholic Steatohepatitis.
Wang X; Cai B; Yang X; Sonubi OO; Zheng Z; Ramakrishnan R; Shi H; Valenti L; Pajvani UB; Sandhu J; Infante RE; Radhakrishnan A; Covey DF; Guan KL; Buck J; Levin LR; Tontonoz P; Schwabe RF; Tabas I
Cell Metab; 2020 May; 31(5):969-986.e7. PubMed ID: 32259482
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of hedgehog ligands in human simple steatosis may protect against nonalcoholic steatohepatitis: Is TAZ a crucial regulator?
Khajehahmadi Z; Mohagheghi S; Nikeghbalian S; Geramizadeh B; Khodadadi I; Karimi J; Ghaffari ME; Tavilani H
IUBMB Life; 2019 Sep; 71(9):1382-1390. PubMed ID: 31087761
[TBL] [Abstract][Full Text] [Related]
7. Low MBOAT7 expression, a genetic risk for MASH, promotes a pro-fibrotic pathway involving hepatocyte TAZ upregulation.
Moore MP; Wang X; Kennelly JP; Shi H; Ishino Y; Kano K; Aoki J; Cherubini A; Ronzoni L; Guo X; Chalasani NP; Khalid S; Saleheen D; Mitsche MA; Rotter JI; Yates KP; Valenti L; Kono N; Tontonoz P; Tabas I
Hepatology; 2024 May; ():. PubMed ID: 38776184
[TBL] [Abstract][Full Text] [Related]
8. Hepatocyte-specific loss of LAP2α protects against diet-induced hepatic steatosis, steatohepatitis, and fibrosis in male mice.
Upadhyay KK; Choi EK; Foisner R; Omary MB; Brady GF
Am J Physiol Gastrointest Liver Physiol; 2023 Aug; 325(2):G184-G195. PubMed ID: 37366543
[TBL] [Abstract][Full Text] [Related]
9. A Therapeutic Silencing RNA Targeting Hepatocyte TAZ Prevents and Reverses Fibrosis in Nonalcoholic Steatohepatitis in Mice.
Wang X; Sommerfeld MR; Jahn-Hofmann K; Cai B; Filliol A; Remotti HE; Schwabe RF; Kannt A; Tabas I
Hepatol Commun; 2019 Sep; 3(9):1221-1234. PubMed ID: 31497743
[TBL] [Abstract][Full Text] [Related]
10. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
Mridha AR; Wree A; Robertson AAB; Yeh MM; Johnson CD; Van Rooyen DM; Haczeyni F; Teoh NC; Savard C; Ioannou GN; Masters SL; Schroder K; Cooper MA; Feldstein AE; Farrell GC
J Hepatol; 2017 May; 66(5):1037-1046. PubMed ID: 28167322
[TBL] [Abstract][Full Text] [Related]
11. Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population.
Nielsen MJ; Leeming DJ; Goodman Z; Friedman S; Frederiksen P; Rasmussen DGK; Vig P; Seyedkazemi S; Fischer L; Torstenson R; Karsdal MA; Lefebvre E; Sanyal AJ; Ratziu V
J Hepatol; 2021 Dec; 75(6):1292-1300. PubMed ID: 34454994
[TBL] [Abstract][Full Text] [Related]
12. Hepatocyte-specific TAZ deletion downregulates p62/ Sqstm1 expression in nonalcoholic steatohepatitis.
Yang X; Sheng S; Du X; Su W; Tian J; Zhao X
Biochem Biophys Res Commun; 2021 Jan; 535():60-65. PubMed ID: 33341674
[TBL] [Abstract][Full Text] [Related]
13. ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD.
Corey KE; Pitts R; Lai M; Loureiro J; Masia R; Osganian SA; Gustafson JL; Hutter MM; Gee DW; Meireles OR; Witkowski ER; Richards SM; Jacob J; Finkel N; Ngo D; Wang TJ; Gerszten RE; Ukomadu C; Jennings LL
J Hepatol; 2022 Jan; 76(1):25-33. PubMed ID: 34600973
[TBL] [Abstract][Full Text] [Related]
14. Reduced lipoapoptosis, hedgehog pathway activation and fibrosis in caspase-2 deficient mice with non-alcoholic steatohepatitis.
Machado MV; Michelotti GA; Pereira Tde A; Boursier J; Kruger L; Swiderska-Syn M; Karaca G; Xie G; Guy CD; Bohinc B; Lindblom KR; Johnson E; Kornbluth S; Diehl AM
Gut; 2015 Jul; 64(7):1148-57. PubMed ID: 25053716
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-223 Ameliorates Nonalcoholic Steatohepatitis and Cancer by Targeting Multiple Inflammatory and Oncogenic Genes in Hepatocytes.
He Y; Hwang S; Cai Y; Kim SJ; Xu M; Yang D; Guillot A; Feng D; Seo W; Hou X; Gao B
Hepatology; 2019 Oct; 70(4):1150-1167. PubMed ID: 30964207
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study.
Vali Y; Lee J; Boursier J; Petta S; Wonders K; Tiniakos D; Bedossa P; Geier A; Francque S; Allison M; Papatheodoridis G; Cortez-Pinto H; Pais R; Dufour JF; Leeming DJ; Harrison SA; Chen Y; Cobbold JF; Pavlides M; Holleboom AG; Yki-Jarvinen H; Crespo J; Karsdal M; Ostroff R; Zafarmand MH; Torstenson R; Duffin K; Yunis C; Brass C; Ekstedt M; Aithal GP; Schattenberg JM; Bugianesi E; Romero-Gomez M; Ratziu V; Anstee QM; Bossuyt PM;
Lancet Gastroenterol Hepatol; 2023 Aug; 8(8):714-725. PubMed ID: 36958367
[TBL] [Abstract][Full Text] [Related]
17. Hepatic sonic hedgehog protein expression measured by computer assisted morphometry significantly correlates with features of non-alcoholic steatohepatitis.
Estep M; Mehta R; Bratthauer G; Alaparthi L; Monge F; Ali S; Abdelatif D; Younoszai Z; Stepanova M; Goodman ZD; Younossi ZM
BMC Gastroenterol; 2019 Feb; 19(1):27. PubMed ID: 30744560
[TBL] [Abstract][Full Text] [Related]
18. Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis.
Wang Q; Zhou H; Bu Q; Wei S; Li L; Zhou J; Zhou S; Su W; Liu M; Liu Z; Wang M; Lu L
J Hepatol; 2022 Aug; 77(2):312-325. PubMed ID: 35292349
[TBL] [Abstract][Full Text] [Related]
19. A TNFα/Miz1-positive feedback loop inhibits mitophagy in hepatocytes and propagates non-alcoholic steatohepatitis.
Jin K; Shi Y; Zhang H; Zhangyuan G; Wang F; Li S; Chen C; Zhang J; Wang H; Zhang W; Sun B
J Hepatol; 2023 Aug; 79(2):403-416. PubMed ID: 37040844
[TBL] [Abstract][Full Text] [Related]
20. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice.
Xu B; Jiang M; Chu Y; Wang W; Chen D; Li X; Zhang Z; Zhang D; Fan D; Nie Y; Shao F; Wu K; Liang J
J Hepatol; 2018 Apr; 68(4):773-782. PubMed ID: 29273476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
